2/26
09:21 am
gild
Gilead Sciences (GILD) had its price target raised by Daiwa Securities Group Inc. from $129.00 to $161.00. They now have an "outperform" rating on the stock.
Low
Report
Gilead Sciences (GILD) had its price target raised by Daiwa Securities Group Inc. from $129.00 to $161.00. They now have an "outperform" rating on the stock.
2/26
08:34 am
gild
CNBC Changemakers and Power Players Podcast: Gilead Sciences Chief Commercial & Corporate Affairs Officer and 2026 CNBC Changemaker Johanna Mercier on ending HIV epidemic, life hacks, and her leadership superpower [CNBC]
Low
Report
CNBC Changemakers and Power Players Podcast: Gilead Sciences Chief Commercial & Corporate Affairs Officer and 2026 CNBC Changemaker Johanna Mercier on ending HIV epidemic, life hacks, and her leadership superpower [CNBC]
2/25
01:54 pm
gild
Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy [Yahoo! Finance]
Low
Report
Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy [Yahoo! Finance]
2/25
01:44 pm
gild
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
Low
Report
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
2/25
07:18 am
gild
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question [Yahoo! Finance]
Low
Report
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question [Yahoo! Finance]
2/24
03:16 pm
gild
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion [Yahoo! Finance]
Low
Report
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion [Yahoo! Finance]
2/23
04:25 pm
gild
Gilead Sciences to Present at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Gilead Sciences to Present at Upcoming Investor Conferences [Yahoo! Finance]
2/23
04:05 pm
gild
Gilead Sciences to Present at Upcoming Investor Conferences
Low
Report
Gilead Sciences to Present at Upcoming Investor Conferences
2/23
11:23 am
gild
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $170.00 price target on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $170.00 price target on the stock.
2/23
09:23 am
gild
Gilead Sciences to Acquire Arcellx in $7.8 Billion Deal [Yahoo! Finance]
Low
Report
Gilead Sciences to Acquire Arcellx in $7.8 Billion Deal [Yahoo! Finance]
2/23
08:07 am
gild
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion [Yahoo! Finance Canada]
Low
Report
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion [Yahoo! Finance Canada]
2/23
06:46 am
gild
M&A Snapshot: Gilead acquires Arcellx for $7.8B [Seeking Alpha]
Low
Report
M&A Snapshot: Gilead acquires Arcellx for $7.8B [Seeking Alpha]
2/23
06:41 am
gild
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion [CNBC]
Low
Report
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion [CNBC]
2/23
06:10 am
gild
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel [Yahoo! Finance]
Low
Report
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel [Yahoo! Finance]
2/23
06:01 am
gild
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
Low
Report
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
2/22
09:30 pm
gild
Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus [Yahoo! Finance]
Low
Report
Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus [Yahoo! Finance]
2/21
06:31 am
gild
Gilead Sciences (NASDAQ:GILD) was upgraded by analysts at Barclays PLC to a "hold" rating.
Low
Report
Gilead Sciences (NASDAQ:GILD) was upgraded by analysts at Barclays PLC to a "hold" rating.
2/20
02:25 pm
gild
Time To Take Profits On Gilead Sciences (Rating Downgrade) [Seeking Alpha]
Low
Report
Time To Take Profits On Gilead Sciences (Rating Downgrade) [Seeking Alpha]
2/20
09:22 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Argus from $135.00 to $165.00. They now have a "buy" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Argus from $135.00 to $165.00. They now have a "buy" rating on the stock.
2/20
09:00 am
gild
Gilead Sciences (NASDAQ:GILD) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $155.00 price target on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $155.00 price target on the stock.
2/20
07:31 am
gild
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More [Yahoo! Finance]
Low
Report
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More [Yahoo! Finance]
2/19
09:22 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Mizuho from $140.00 to $170.00. They now have an "outperform" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Mizuho from $140.00 to $170.00. They now have an "outperform" rating on the stock.
2/18
09:21 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Rothschild & Co Redburn from $159.00 to $170.00. They now have a "buy" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Rothschild & Co Redburn from $159.00 to $170.00. They now have a "buy" rating on the stock.
2/17
08:30 am
gild
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
Low
Report
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
2/14
09:55 am
gild
Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.82 [Yahoo! Finance]
Low
Report
Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.82 [Yahoo! Finance]